US OptionsDetailed Quotes

HOOK240816C5000

Watchlist

1.95
+0.45+30.00%

15min DelayClose Jul 23 15:59 ET

1.95High1.95Low

HOOKIPA Pharma Stock Discussion

CUP9150

Jul 10 15:28

$HOOKIPA Pharma(HOOK.US)$

Jaguar8

Jul 8 06:03

NEWS

$HOOKIPA Pharma(HOOK.US)$
HOOKIPA Pharma Announces Effective Date of 1-for-10 Reverse Stock Split - July 10,2024

Trytosaveabit

Jul 1 15:36

Update

$HOOKIPA Pharma(HOOK.US)$ HOOKIPA Pharma Inc - HOOKIPA Achieves a $5 Mln Non-Dilutive Milestone Payment Under Its Collaboration and License Agreement With Gilead

FattyChick

Jul 1 15:32

$HOOKIPA Pharma(HOOK.US)$ Good news after-market 👀

LeoforDharma

Jun 20 05:40

Update Insider Buying

$HOOKIPA Pharma(HOOK.US)$
Ladies and gentleman, On the 17 June 2024, 5 directors and 1 chairperson have collectively bought over 340K of shares at around 0.71 $.
Just wanted to share .... 😊

LeoforDharma

Jun 18 10:18

Shorties move away plz

$HOOKIPA Pharma(HOOK.US)$
Up down up down, these shorties will never let us live in peace 🤬🤬🤬

LeoforDharma

Jun 14 12:36

Damn

$HOOKIPA Pharma(HOOK.US)$ @Trytosaveabit
Why is this stock doing so bad? I mean for a clinical stage companythey are even profitable at this quarter means their product must be at least good right ?

Trytosaveabit

Jun 4 12:05

News

$HOOKIPA Pharma(HOOK.US)$ HOOKIPA Pharma Announces Phase 2 Results For HB-200 Combined With Pembrolizumab In HPV16+ Head And Neck Cancer
Benzinga· 1 min ago
Encouraging clinical activity with observed deepening of responses in 35 evaluable first line head and neck patients treated with HB-200 plus pembrolizumab
In a subset of 17 evaluable patients with PD-L1 combined positive score (CPS) of 20 or higher, the Company's selected registrational pivotal trial population, data showed confirmed OR...

Jaguar8

Jun 4 12:01

NEWS

$HOOKIPA Pharma(HOOK.US)$
HOOKIPA Pharma Announces Updated Phase 2 Clinical Data at the American Society of Clinical Oncology 2024 Annual Meeting
HOOKIPA Pharma announced updated Phase 2 clinical data for HB-200 combined with pembrolizumab in treating recurrent/metastatic HPV16+ head and neck cancer at the ASCO 2024 Annual Meeting. Out of 35 evaluable patients, results showed a 37% confirmed objective response rate (ORR), 11% complete response (CR) rate, and 69% disease control rate (DCR). N...

Trytosaveabit

May 25 06:31

Going through my notes here this morning! Decided I would share so you to can make a note. That’s if you wish!

$HOOKIPA Pharma(HOOK.US)$ First though there is to be additional data come out of the ASCO June 4th! Also Researchers intend to present data from investigator initiated trial of HB-200 W/Chemo, on June 3RD! And now to what i wanted to share from my notes that i took in Janu...

No comment yet